Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Sep 24 2021 12:00
    60,048.47 +163.11 ( +0.27%)
  • NIFTY Sep 24 2021 12:00
    17,853.20 +30.25 ( +0.17%)
  • SENSEX Sep 24 2021 12:00
    60,048.47 +163.11 ( +0.27%)
  • NIFTY Sep 24 2021 12:00
    17,853.20 +30.25 ( +0.17%)
  • Nasdaq Sep 24 2021 04:30
    15,052.24 +155.39 ( +1.04%)
  • DJIA Sep 24 2021 04:30
    34,764.82 +506.50 ( +1.48%)
  • S&P 500 Sep 24 2021 04:30
    4,448.98 +53.34 ( +1.21%)
  • Hang Seng Sep 24 2021 02:10
    24,192.16 -318.82 (-1.30%)
  • Crude Oil Sep 24 2021 11:29
    5,466.00 +41.00 ( +0.76%)
  • Gold Sep 24 2021 11:29
    45,995.00 -61.00 (-0.13%)
  • Silver Sep 24 2021 11:29
    59,920.00 -869.00 (-1.43%)
  • Copper Sep 24 2021 11:29
    714.00 +1.35 ( +0.19%)
  • Pound / Rupee Dec 23 2016 22:30
    100.57 0.00 (0.00%)
  • Dollar / Rupee Dec 23 2016 22:30
    73.71 +0.13 ( +0.18%)
  • Euro / Rupee Dec 23 2016 22:30
    86.40 +0.09 ( +0.11%)
  • Yen / Rupee Dec 23 2016 22:30
    0.67 0.00 ( +0.03%)

Cipla Ltd

BSE Code : 500087 | NSE Symbol : CIPLA | ISIN:INE059A01026| SECTOR : Pharmaceuticals |

NSE BSE
 
SMC down arrow

967.00

-1.05 (-0.11%) Volume 280564

24-Sep-2021 EOD

Prev. Close

968.05

Open Price

968.15

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

0.00(0)

 

Today’s High/Low 983.10 - 960.65

52 wk High/Low 997.20 - 706.45

Key Stats

MARKET CAP (RS CR) 78003.41
P/E 29.44
BOOK VALUE (RS) 247.0403669
DIV (%) 250
MARKET LOT 1
EPS (TTM) 32.85
PRICE/BOOK 3.91434004140479
DIV YIELD.(%) 0.52
FACE VALUE (RS) 2
DELIVERABLES (%) 58.45
4

News & Announcements

22-Sep-2021

Cipla Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

22-Sep-2021

Cipla Ltd - Cipla Limited - Loss of Share Certificates

20-Sep-2021

Cipla Ltd - Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates

18-Sep-2021

Cipla Ltd - Announcement under Regulation 30 (LODR)-Acquisition

15-Sep-2021

Cipla allots 2,499 equity shares under ESOS

25-Aug-2021

Cipla enters into JV agreement with Kemwell Biopharma

18-Aug-2021

Cipla allots 8,668 equity shares under ESOP

12-Aug-2021

Cipla receives final approval for Difluprednate Ophthalmic Emulsion

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Alembic Ltd 506235 ALEMBICLTD
Alembic Pharmaceuticals Ltd 533573 APLLTD
Alkem Laboratories Ltd 539523 ALKEM
ANG Lifesciences India Ltd 540694
Anglo-French Drugs & Industries Ltd 40169
Anupam Rasayan India Ltd 543275 ANURAS
Astron Drugs & Industries Ltd 524206
Aurobindo Pharma Ltd 524804 AUROPHARMA
Bajaj Healthcare Ltd 539872
Bal Pharma Ltd 524824 BALPHARMA
Biocon Ltd 532523 BIOCON
Bombay Drugs & Pharma Ltd (Merged) 524512
Brooks Laboratories Ltd 533543 BROOKS
Cadila Healthcare Ltd 532321 CADILAHC
Cebon India Ltd 524272
Celestial Biolabs Ltd 532871 CELESTIAL
Cepham Organics Ltd 507756
Cian Healthcare Ltd 542678
Claris Lifesciences Ltd 533288
Concord Drugs Ltd 538965
Dee-Pharma Ltd 507722 DEEPHARMA
Dishman Carbogen Amcis Ltd 540701 DCAL
Dr Reddys Laboratories Ltd 500124 DRREDDY
Dr Sabharwals Manufacturing Labs Ltd 507743
Dr.Datsons Labs Ltd 533412 DRDATSONS
Druid Pharma Ltd 40430
Earum Pharmaceuticals Ltd 542724
Eupharma Laboratories Ltd 530409 EUPHARMLAB
FDC Ltd 531599 FDC
Glenmark Life Sciences Ltd 543322 GLS
Glenmark Pharmaceuticals Ltd 532296 GLENMARK
Gufic BioSciences Ltd 509079 GUFICBIO
Hindustan Bio Sciences Ltd 532041
Hindustan Biotech Ltd 40162
Indoco Remedies Ltd 532612 INDOCO
Ind-Swift Laboratories Ltd 532305 INDSWFTLAB
IOL Chemicals & Pharmaceuticals Ltd 524164 IOLCP
Ipca Laboratories Ltd 524494 IPCALAB
J B Chemicals & Pharmaceuticals Ltd 506943 JBCHEPHARM
Jagsonpal Pharmaceuticals Ltd 507789 JAGSNPHARM
Jayant Vitamins Ltd 506518
Jupiter Bioscience Ltd 524826 JUPITER
KDL Biotech Ltd 532291 KOPDRUGS
Kopran Ltd 524280 KOPRAN
Kothari Phytochemicals & Industries Ltd 40136
Lasa Supergenerics Ltd 540702 LASA
Lupin Laboratories Ltd (Merged) 500258 LUPINLAB
Lyka Labs Ltd 500259 LYKALABS
Mangalam Drugs and Organics Ltd 532637 MANGALAM
Medico Remedies Ltd 540937
Mercury Phytochem Ltd 524498
Merind Ltd 506895 MARIND
Mesco Pharmaceuticals Ltd 500274 MESCOPHARM
Morepen Laboratories Ltd 500288 MOREPENLAB
Mylan Laboratories Ltd 524794 MATRIXLABS
Natco Pharma Ltd 524816 NATCOPHARM
Oriental Remedies & Herbals Ltd 526989
Ortin Laboratories Ltd 539287 ORTINLAB
P C I Chemicals & Pharmaceuticals Ltd 524792
Pan Drugs Ltd 531440
Panacea Biotec Ltd 531349 PANACEABIO
Parnax Lab Ltd 506128
Phaarmasia Ltd 523620
Pharmaceutical Products of India Ltd 524113 PPIL
Piramal Enterprises Ltd 500302 PEL
Ranbaxy Laboratories Ltd (Merged) 500359 RANBAXY
RPG Life Sciences Ltd 532983 RPGLIFE
Saamya Biotech (India) Ltd 532905
Sakar Healthcare Ltd 538377 SAKAR
Sandoz (India) Ltd (Merged) 531990
Sharda Drugs & Industries Ltd 24206
Shree Ganesh Biotech India Ltd 539470
Shree Ganesh Remedies Ltd 540737
Siddhartha Pharmachem Ltd 532122
SMS Lifesciences India Ltd 540679 SMSLIFE
Socrus Bio Sciences Ltd 524719
SOL Pharmaceuticals Ltd 500393 SOLPHARMA
Solara Active Pharma Sciences Ltd 541540 SOLARA
Source Natural Foods & Herbal Supplements Ltd 531398
Strides Pharma Science Ltd 532531 STAR
Sumitra Pharmaceutical & Chemicals Ltd (Merged) 524133 SUMITRAPHA
Sun Pharmaceuticals Industries Ltd 524715 SUNPHARMA
Supriya Pharmaceuticals Ltd 524784
Surya Pharmaceutical Ltd 532516 SURYAPHARM
Suven Pharmaceuticals Ltd 543064 SUVENPHAR
Syngene International Ltd 539268 SYNGENE
Syschem (India) Ltd 531173
Themis Medicare Ltd 530199 THEMISMED
Titan Biotech Ltd 524717
Tonira Pharma Ltd(merged) 530155
Torrent Pharmaceuticals Ltd 500420 TORNTPHARM
Triochem Products Ltd 512101
TTK Healthcare Ltd 507747 TTKHLTCARE
Unichem Laboratories Ltd 506690 UNICHEMLAB
Unicorn Pharmaceuticals (India) Ltd 524334
Valencia Nutrition Ltd 542910
Vardhaman Laboratories Ltd 524796
Vikram Thermo (India) Ltd 530477
Vineet Laboratories Ltd 543298 VINEETLAB
Vivimed Labs Ltd 532660 VIVIMEDLAB
Welcure Drugs & Pharmaceuticals Ltd 524661
Wintac Ltd 524758
Wockhardt Ltd 532300 WOCKPHARMA
Zillion Pharmachem Ltd 524476 ZILONPHARM
Zota Health Care Ltd 538426 ZOTA

Share Holding

Category No. of shares Percentage
Total Foreign 207247334 25.70
Total Institutions 130822363 16.22
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 38078838 4.72
Total Promoters 295674971 36.66
Total Public & others 134773247 16.70
Total 806596753 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Cipla Ltd

Cipla Ltd is one of the leading pharmaceutical companies in India. The company focuses on development of new formulations and has a wide range of pharmaceutical products. The product portfolio includes over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company set up first research division for attaining self-sufficiency in technological development. In the year 1960, they started operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. In the year 1968, the company manufactured ampicillin for the first time in the country. In the year 1972, the company started Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. In the year 1976, they launched medicinal aerosols for asthma. In the year 1980, the company won Chemexcil Award for Excellence for exports. In the year 1982, the company started operations in their fourth factory at Patalganga, Maharashtra. In the year 1984, they developed anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Also, they won Sir P C Ray Award for developing in-house technology for indigenous manufacture of a number of basic drugs. In the year 1985, US FDA approved the company's bulk drug manufacturing facilities. In the year 1988, they won National Award for Successful Commercialisation of Publicly Funded R&D. In the year 1991, the company launched etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. Also, they manufactured antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. In the year 1994, the company commenced commercial operations in their fifth factory at Kurkumbh, Maharashtra. In the year 1997, they launched transparent Rotahaler, the world's first such dry powder inhaler device. In the year 1998, they launched lamivudine. The company becomes one of the few companies in the world to offer all three component drugs of retroviral combination therapy. In the year 1999, the company launched Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. In the year 2000, the company became the first company, outside the USA and Europe to launch CFC-free inhalers - ten years before the deadline to phase out use of CFC in medicinal products. In the year 2002, the company set up four state-of-the-art manufacturing facilities in Goa. In the year 2003, they launched TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Also, they commissioned second phase of manufacturing operations at Goa. In the year 2005, the company set up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. In the year 2007, they set up state-of-the-art facility for manufacture of formulations at Sikkim. In February 2007, the company entered into a development and supply agreement with Drugs for Neglected Diseases Initiative (DNDi), a global non-profit organization, for a new anti-malarial combination drug as a global initiative. During the year 2009-10, the company sold their intellectual property rights and technical know-how of 'i-pill', an emergency contraceptive brand, to Piramal Healthcare Ltd, for the territory of India, at an aggregate consideration of Rs 95 crore. Also, they entered into a strategic alliance with Stempeutics Research Pvt. Ltd., promoted by the Manipal Group, for the marketing rights of stem-cell-based products being developed by Stempeutics. Cipla is sponsoring up to Rs.50 crore, in the initial phase, for research and development of these products. In April 2010, the company commenced commercial production of pharmaceutical formulations at the Special Economic Zone (SEZ) project, at Indore, Madhya Pradesh. This project includes facilities for the manufacture of aerosols, respules, liquid orals, pre-filled syringes (PFS), nasal sprays, large volume parenterals (LVP), eye drops, tablets and capsules. The total investment for this project is about Rs 900 crore. In May 2010, the company acquired an undertaking for Rs 30.64 crore, by way of a slump sale arrangement. The undertaking has a manufacturing facility, approved by US FDA and WHO, for APIs and intermediates. It is located at Kurkumbh (Pune district). Also, the company set up a wholly-owned subsidiary, 'Cipla Singapore Pte Ltd', in Singapore to aid logistics and distribution of the company's export business. In May 2010, the company acquired 100% shareholding of a company for Rs 51.38 crore. This company has a state-of-the-art formulations manufacturing facility at Sikkim with capabilities to manufacture tablets, capsules, oral liquids, injections, dry syrup and ointments/creams. During the year 2010-11, the company introduced a number of new drugs and formulations, such as Entavir (entecavir tablets), an antiviral for hepatitis B; Febucip (febuxostat tablets), a drug for gout; Flosoft (fluorometholone acetate ophthalmic suspension), a topical steroid for eye inflammation; Foracort (formoterol and budesonide autohaler), an asthma controller therapy in a new easy-to-use breath actuated inhaler; Furamist AZ (fluticasone furoate and azelastine hydrochloride nasal spray), a nasal spray for allergic rhinitis, and Montair FX (montelukast and fexofenadine tablets), an antiallergic combination for rhinitis. During the year, Cipla (Mauritius) Ltd, Cipla (UK) Ltd, Cipla-Oz Pty Ltd, Four M Propack Pvt Ltd, Goldencross Pharma Pvt Ltd, Medispray Laboratories Pvt Ltd, Meditab Holdings Ltd, Meditab Pharmaceuticals South Africa (Pty) Ltd, Meditab Specialities New Zealand Ltd, Meditab Specialities Pvt Ltd, Sitec Labs Pvt Ltd and STD Chemicals Ltd. The company is setting up API facilities at Bengaluru and Kurkumbh. They are also upgrading the API facilities at Patalganga. The total investment for these projects is about Rs 400 crore. The company proposes to subscribe to the share capital of two biotechnology companies, located in India and Hong Kong, to obtain a 40 per cent and a 25 per cent share, respectively. The total investment will be about USD 65 million, in a phased manner, for setting up state-of-the-art facilities for biosimilar products in Goa and China. On 3 May 2012, Cipla announced a major price reduction in selected cancer drugs. On 21st July 2012, Cipla announced collaboration with Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS. On 14 August 2012, Cipla announced the launch of Qvir', a novel 4 drug kit priced at Rs 158 for treating HIV/AIDS. On 8 November 2012, Cipla announced a major price reduction on select anti-cancer drugs. On 27 February 2013, Cipla announced an offer to the shareholders of Cipla Medpro South Africa Ltd. (Medpro) to acquire 100% of the ordinary share capital of Medpro for ZAR 10.0 per share via a scheme of arrangement. The Board of Directors of Medpro unanimously resolved to support and facilitate Cipla's offer and recommended to Medpro shareholders that they vote in favour of all resolutions required to implement the scheme of arrangement. Cipla Medpro South Africa is a leading provider of chronic medicines to the public and private sectors. On 16 July 2013, Cipla announced that it had completed the acquisition of 100% of the issued shares of Cipla Medpro South Africa Ltd. for an aggregate consideration of ZAR 4507mn (Rs 2707 crore). On 17 April 2013, Cipla announced the launch of the first biosimilar of Etanercept in India for the treatment of rheumatic disorders. On 20 February 2014, Cipla and MSD announced the formation of an India-specific strategic partnership whereby Cipla will have a non-exclusive license to market, promote and distribute MSD's raltegravir 400mg tablet, under a different brand name in India. The drug is used for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. On 12 May 2014, Cipla through its wholly owned subsidiary, Cipla (EU) Limited announced $21 million two-phase investment in Chase Pharmaceuticals Corporation Inc., US (Chase) to support Alzheimer's disease drug development. On 19 June 2014, Cipla announced that it has collaborated with Hetero to launch a biosimilar of the drug Darbepoetin alfa' under the brand name Actorise'. The product is indicated for the treatment of anaemia caused due to chronic kidney disease. On 7 July 2014, Cipla announced its intention to make investments of up to 100 million in its UK subsidiary over the next few years. The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as well as research and development, clinical trials and further expansion internationally and in the UK. In its bid to enter the markets of Czech Republic and Slovaki, Cipla on 8 September 2014 announced commercial collaboration with UK-based S&D Pharma. On 15 September 2014, Cipla announced that it had signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of Sofosbuvir mono, Ledipasvir mono, the fixed-dose combination of Ledipasvir/Sofosbuvir with each other and the combination of Sofosbuvir or Ledipasvir with other active substances, for the treatment of hepatitis C. On 18 September 2014, Cipla announced that it has granted Salix Pharmaceuticals, Inc., a US-based speciality pharmaceutical company, exclusive rights under certain patent applications in the Rifaximin Complexes' patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. On 8 October 2014, Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro announced that it had entered into sales and distribution arrangement with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world for the territory of South Africa. As per the tie-up, Cipla Medpro, a 100% subsidiary of Cipla Limited, will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. On 9 February 2015, Cipla announced that its wholly owned subsidiary, Cipla (EU) Limited, U.K. has entered into a joint venture (JV) agreement with Cipla's existing business partners in Morocco - Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and The Pharmaceutical Institute (PHI). This JV is aimed at strengthening Cipla's presence in Morocco, which is in-line with its global growth strategy to build front-end presence in key markets. On 13 February 2015, Cipla announced that it has been awarded USD 188.95 million of Global Fund ARV Tender for anti-retrovirals drugs. The Global Fund is a 21st- century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. On 21 July 2015, Cipla announced that its board of directors approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II Limited or its affiliates, in its newly launched consumer healthcare business which is under incorporation. On 4 September, 2015, Cipla announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc for $550 million in an all cash transaction. InvaGen Pharmaceuticals is a leading generic pharmaceutical company in the US. Exelan Pharmaceuticals is a privately held sales and marketing company, with a focus on generic pharmaceuticals for the government and institutional market in the US. On 18 February 2016, Cipla announced that its UK arm, Cipla (EU) Limited had successfully completed the acquisition of InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The acquisition was made by Cipla (EU) Limited through a wholly owned special purpose vehicle which would merge into InvaGen Pharmaceuticals Inc. after the acquisition. On 8 October 2015, Cipla announced that its South African subsidiary Cipla Medpro (Pty) Ltd. entered into an exclusive agreement with the world's largest vaccine manufacturer, Serum Institute of India (SII) to provide vaccines in South Africa. On 29 October 2015, Cipla announced that it had entered into a definitive agreement to sell its entire 25% stake in Biomab Holding Limited, Hong Kong (BHL) to Biomab Brilliant Limited, British Virgin Islands which holds the remaining 75% stake in BHL, for a total consideration of USD 25,775,000. Biomab Holding Limited is focused on developing Biosimilars for the Chinese market. On 21 December 2015, Cipla announced the launch of generic drug Ledipasvir-Sofosbuvir in India under the brand name Hepcvir-L. Hepcvir-L is the first once-a-day, fixed-dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. On 6 January 2016, BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India. On 12 October 2016, Cipla announced that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility, indicating formal closure of the US FDA inspection conducted in July/August, 2015. On 23 November 2016, Cipla announced that Chase Pharmaceuticals Corporation, a Delaware based corporation (Chase) in which Cipla Limited's UK arm, Cipla (EU) Limited (Cipla UK) has 16.7% stake, has been acquired by a subsidiary of Allergan, plc. Allergan agreed to pay $125 million upfront plus potential regulatory and commercial milestones of up to $875 million to the shareholders of Chase. Cipla UK acquired a minority stake in Chase in May 2014 via a syndicated venture investment. On 17 February 2017, Cipla announced the launch of adult Hepatitis B vaccine in India. Under a co-exclusive agreement with Serum Institute of India Private Limited (SII), Cipla will market the vaccine for adults while SII will market it for adults and children. On 4 March 2017, Cipla announced that it had entered into agreements, through its Wholly Owned Subsidiary Inyanga Trading 386 Proprietary Limited (Inyanga), with the group companies of Ascendis Health Limited, South Africa for divesting its animal health business in South Africa and Sub-Saharan Africa. On 6 April 2017, Cipla announced that its wholly owned subsidiary in USA Cipla USA Inc. signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity. On 30 November 2017, Cipla announced that it had received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. During FY18, Anmarat (Pty) Limited was acquired in South Africa as a part of strategy to strengthen OTC portfolio and Cipla Technologies LLC was incorporated in USA to build speciality product portfolio for Cipla. During FY18, two non-operating companies viz., Meditab Specialities New Zealand Ltd and Cipla Pharma Nigeria Ltd were deregistered. As a part of strategy, the Company has divested its entire stake in Cipla Croatia d.o.o., Croatia, Al Jabal For Drugs And Medical Appliances Company Ltd, Yemen, Cipla Agrimed Proprietary Ltd and Cipla Vet Proprietary Ltd., in South Africa. As on 31st March, 2018, it has 49 subsidiaries and 1 associate. During the FY18,the company invested Rs 816 crore on capital expenditure, over Rs 300 crore lower than the previous year. During the FY19, Madison Pharmaceuticals Inc. was incorporated in USA and Cipla Gulf FZ- LLC in Dubai for strengthening its business operations. In South Africa, Mirren (Pty) Limited was acquired as a part of strategy to strengthen its OTC portfolio. In USA, 33.3% stake was acquired in Avenue Therapeutics Inc. for building specialty business in USA. The Company's wholly owned subsidiary Goldencross Pharma Private Limited acquired minority stake i.e. 11.71% in Wellthy Therapeutics Private Limited. During the 2018-19, 4 non-operating subsidiaries viz. Xeragen Laboratories (Pty) Limited, Galilee Marketing (Pty) Ltd, Med Man Care (Pty) Ltd in South Africa and Cipla FZE in Dubai were liquidated. The company had 48 subsidiaries and 2 associates as on 31st March, 2019. During the FY2019, the Company invested Rs 504 crore in capital expenditure (net off sales proceeds), which is lower by Rs 200 crore from the previous year. During the FY2020, Incorporation of Cipla Pharmaceuticals Limited in India for setting up facilities for DPI dosage and for further expansion of MDI and FFS Respule Dosage, Cipla (Colombia) SAS in Colombia and Cipla (China) Pharmaceutical Co. Limited in China for strengthening its business portfolio in foreign markets. Also incorporation of Cipla (Jiangsu) Pharmaceutical Co, Limited as Joint venture between Cipla (EU) Limited and Jiangsu Acebright Pharmaceutical Co. Limited for exploring business opportunities and manufacture of pharmaceutical products in China. The company also acquired the remaining 40% stake in Cipla Pharma Lanka Private Limited (CPL) by Cipla (EU) Limited, to further strengthen its presence in Sri Lanka. Upon acquisition CPL has become a wholly owned subsidiary of Cipla (EU) Limited. Also acquired 30% stake in Brandmed (Pty) Limited by Cipla Medpro South Africa (Pty) Limited to enhance its diversified portfolio in the noncommunicable diseases area. The company also acquired 26% stake in AMPSolar Power Systems Private Limited to enhance the proportion of renewable (solar) based power consumption, and to comply with regulatory requirement for captive power consumption under electricity laws. The company also liquidated Tasfiye Halinde Cipla ila Ticaret Anonim Sirketi, Turkey. The company had 51 subsidiaries and 4 associates as on 31st March, 2020. Cipla won the Digital Supply Chain Enterprise Award' at the 9th edition of the Manufacturing Supply Chain Awards 2020. During the FY2021, The Group has divested its stake in two of its subsidiaries namely Quality Chemical Limited (Group share - 51.18%) and Anmarat Proprietary Limited (wholly owned subsidiary). The Board in its meeting held on 29th January, 2021 has approved a draft scheme of arrangement (Scheme) which entails demerger of the US business undertaking (Demerged Undertaking 1) of Cipla Limited (Demerged Company) into its wholly-owned subsidiary, Cipla BioTec Limited (Resulting Company 1) and consumer business undertaking (Demerged Undertaking 2) of Cipla Limited into its wholly-owned subsidiary, Cipla Health Limited (Resulting Company 2) pursuant to Sections 230 to 232 and the other relevant provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said Scheme would be subject to the receipt of requisite approvals including from the National Company Law Tribunal, BSE Limited, National Stock Exchange of India Limited and Securities and Exchange Board of India, the shareholders and/or creditors of the Demerged Company, Resulting Company 1 and Resulting Company 2. On 30th March 2021, the Company made a strategic investment of Rs 40 Crore in ABCD Technologies LLP. On 10th May, 2021, Cipla Technologies LLC (Ciptec'), a subsidiary of the Group has received an anticipatory material breach notice under Development and Commercialization Agreement with Pulmatrix on co-development of Pulmazole. The Company will suitably respond to the said notice. As on 31 March 2021,the company had 55 subsidiaries and 5 associate companies under its roof.

Cipla Ltd Chairman Speech

"Guided by our legacy and humanitarian approach, Cipla has once again been at the forefront in fighting pandemics, be it HIV/AIDS, Bird-Flu, Swine-Flu and now COVID-19. We are providing a wide range of essential medications and will continue to do everthing in our capacity in the relentless battle to combat COVID-19.''

Dear Shareholders,

The last time I addressed all of you was at our 84th AGM. At that time, the COVID-19 pandemic had already caused massive disruptions worldwide across every aspect of human life. This led to an adverse economic, political and social impact on people, society, communities and countries. We could not fathom the intensity and magnitude of COVID-19 on humanity. We are here today a year down the road, facing a massive second wave of the COVID-19 affliction. There is a great deal of fear, panic and uncertainty among the people, particularly as the virus continues to mutate causing further hardships as the intensity mounts.

I have never witnessed a global crisis of this magnitude. My sincere plea to all is to look after yourself, your families, your friends and colleagues and be as careful and disciplined as possible.

In order to tackle this unforeseen pandemic, everyone is working relentlessly and pooling their knowledge and resources.

This includes the Government, public institutions, healthcare professionals, organisations and multilateral agencies, pharmaceutical companies and citizens. My heartfelt gratitude to our employees for their remarkable dedication, beyond the call of duty, for working round the clock to help combat the ongoing challenges of manufacturing and supply of vital medicines.

I would like to take this opportunity to applaud the stellar work being done by all our managers, staff and workers throughout India and our global establishments. Guided by our legacy and humanitarian approach, Cipla has once again been at the forefront in fighting pandemics, be it HIV/AIDS, Bird- Flu, Swine-Flu and now COVID-19. We are providing a wide range of essential medications and will continue to do everthing in our capacity in the relentless battle to combat COVID-19. India must overcome this pandemic as quickly as possible. We consider it our duty and responsibility to alleviate pain and provide care. Through Cipla Foundation, we will continue to address critical needs of the community by strengthening CovidCare facilities, provide life-saving medical equipment and bring testing within reach of patients.

Cipla is a leading partner of choice for several innovator companies, who are producing critical drugs for COVID-19. We have ongoing partnerships with Gilead, Novartis, Boehringer Ingelheim, Johnson & Johnson, Roche, Lilly, Merck, etc. and within India, we have partnered with Indian Council of Medical Research (ICMR), Council of Scientific & Industrial Research (CSIR) and many private organisations such as KARWA, Premier Medical Corporation and others for commercialisation of medicines and diagnostics. Expanding our role beyond providing medicines alone, Cipla is among the leading Indian pharmaceutical companies offering solutions against COVID-19 across the spectrum, which includes awareness, prevention, diagnosis, treatment and care.

This is a time for companies like ours to demonstrate solidarity and support each other to ensure affordable and accessible drugs. This type of collaboration is of the utmost importance, particularly between the developed and the developing countries.

As an organisation, we have always believed that a healthy community will lead to a healthy and prosperous country. Access to medicines at affordable prices is a fundamental and a basic human right. This is an opportune time for India to build a robust healthcare system, where none should be denied medication.

Cipla is now an 85-year-old company, and the journey so far has been fraught with unexpected obstacles and hurdles which we have resolutely overcome. Today, our Company has grown and progressed to being one of the leading pharmaceutical organisations. This has been possible because of our compassionate approach to medicine and healthcare that goes beyond the pursuit of profit and growth. We have always been a "people-first" organsiation and I am thankful for the contribution of all past and present employees for their commitment and passion. They are the reason behind making our journey memorable.

I would like to convey my sincere gratitude to all stakeholders in the Company, our board members, senior management, shareholders, healthcare professionals, the industry and most importantly all of you for your contributions to Cipla. The on-going pandemic has taught us many lessons. Among these is our need to focus on new drug developments and work in partnership with our colleagues in the industry, both in India and internationally to improve the quality of life for humanity.

Currently, we are doing our best to combat COVID-19 and hope that the world will overcome this pandemic and we will all emerge stronger as a community. Cipla will continue to contribute towards our mission of 'Caring for Life'. As always, my warmest wishes to all of you and your families.

Warm Regards,

Y K Hamied

Chairman.

   

Cipla Ltd Company History

Cipla Ltd is one of the leading pharmaceutical companies in India. The company focuses on development of new formulations and has a wide range of pharmaceutical products. The product portfolio includes over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company set up first research division for attaining self-sufficiency in technological development. In the year 1960, they started operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. In the year 1968, the company manufactured ampicillin for the first time in the country. In the year 1972, the company started Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. In the year 1976, they launched medicinal aerosols for asthma. In the year 1980, the company won Chemexcil Award for Excellence for exports. In the year 1982, the company started operations in their fourth factory at Patalganga, Maharashtra. In the year 1984, they developed anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Also, they won Sir P C Ray Award for developing in-house technology for indigenous manufacture of a number of basic drugs. In the year 1985, US FDA approved the company's bulk drug manufacturing facilities. In the year 1988, they won National Award for Successful Commercialisation of Publicly Funded R&D. In the year 1991, the company launched etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. Also, they manufactured antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. In the year 1994, the company commenced commercial operations in their fifth factory at Kurkumbh, Maharashtra. In the year 1997, they launched transparent Rotahaler, the world's first such dry powder inhaler device. In the year 1998, they launched lamivudine. The company becomes one of the few companies in the world to offer all three component drugs of retroviral combination therapy. In the year 1999, the company launched Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. In the year 2000, the company became the first company, outside the USA and Europe to launch CFC-free inhalers - ten years before the deadline to phase out use of CFC in medicinal products. In the year 2002, the company set up four state-of-the-art manufacturing facilities in Goa. In the year 2003, they launched TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Also, they commissioned second phase of manufacturing operations at Goa. In the year 2005, the company set up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. In the year 2007, they set up state-of-the-art facility for manufacture of formulations at Sikkim. In February 2007, the company entered into a development and supply agreement with Drugs for Neglected Diseases Initiative (DNDi), a global non-profit organization, for a new anti-malarial combination drug as a global initiative. During the year 2009-10, the company sold their intellectual property rights and technical know-how of 'i-pill', an emergency contraceptive brand, to Piramal Healthcare Ltd, for the territory of India, at an aggregate consideration of Rs 95 crore. Also, they entered into a strategic alliance with Stempeutics Research Pvt. Ltd., promoted by the Manipal Group, for the marketing rights of stem-cell-based products being developed by Stempeutics. Cipla is sponsoring up to Rs.50 crore, in the initial phase, for research and development of these products. In April 2010, the company commenced commercial production of pharmaceutical formulations at the Special Economic Zone (SEZ) project, at Indore, Madhya Pradesh. This project includes facilities for the manufacture of aerosols, respules, liquid orals, pre-filled syringes (PFS), nasal sprays, large volume parenterals (LVP), eye drops, tablets and capsules. The total investment for this project is about Rs 900 crore. In May 2010, the company acquired an undertaking for Rs 30.64 crore, by way of a slump sale arrangement. The undertaking has a manufacturing facility, approved by US FDA and WHO, for APIs and intermediates. It is located at Kurkumbh (Pune district). Also, the company set up a wholly-owned subsidiary, 'Cipla Singapore Pte Ltd', in Singapore to aid logistics and distribution of the company's export business. In May 2010, the company acquired 100% shareholding of a company for Rs 51.38 crore. This company has a state-of-the-art formulations manufacturing facility at Sikkim with capabilities to manufacture tablets, capsules, oral liquids, injections, dry syrup and ointments/creams. During the year 2010-11, the company introduced a number of new drugs and formulations, such as Entavir (entecavir tablets), an antiviral for hepatitis B; Febucip (febuxostat tablets), a drug for gout; Flosoft (fluorometholone acetate ophthalmic suspension), a topical steroid for eye inflammation; Foracort (formoterol and budesonide autohaler), an asthma controller therapy in a new easy-to-use breath actuated inhaler; Furamist AZ (fluticasone furoate and azelastine hydrochloride nasal spray), a nasal spray for allergic rhinitis, and Montair FX (montelukast and fexofenadine tablets), an antiallergic combination for rhinitis. During the year, Cipla (Mauritius) Ltd, Cipla (UK) Ltd, Cipla-Oz Pty Ltd, Four M Propack Pvt Ltd, Goldencross Pharma Pvt Ltd, Medispray Laboratories Pvt Ltd, Meditab Holdings Ltd, Meditab Pharmaceuticals South Africa (Pty) Ltd, Meditab Specialities New Zealand Ltd, Meditab Specialities Pvt Ltd, Sitec Labs Pvt Ltd and STD Chemicals Ltd. The company is setting up API facilities at Bengaluru and Kurkumbh. They are also upgrading the API facilities at Patalganga. The total investment for these projects is about Rs 400 crore. The company proposes to subscribe to the share capital of two biotechnology companies, located in India and Hong Kong, to obtain a 40 per cent and a 25 per cent share, respectively. The total investment will be about USD 65 million, in a phased manner, for setting up state-of-the-art facilities for biosimilar products in Goa and China. On 3 May 2012, Cipla announced a major price reduction in selected cancer drugs. On 21st July 2012, Cipla announced collaboration with Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS. On 14 August 2012, Cipla announced the launch of Qvir', a novel 4 drug kit priced at Rs 158 for treating HIV/AIDS. On 8 November 2012, Cipla announced a major price reduction on select anti-cancer drugs. On 27 February 2013, Cipla announced an offer to the shareholders of Cipla Medpro South Africa Ltd. (Medpro) to acquire 100% of the ordinary share capital of Medpro for ZAR 10.0 per share via a scheme of arrangement. The Board of Directors of Medpro unanimously resolved to support and facilitate Cipla's offer and recommended to Medpro shareholders that they vote in favour of all resolutions required to implement the scheme of arrangement. Cipla Medpro South Africa is a leading provider of chronic medicines to the public and private sectors. On 16 July 2013, Cipla announced that it had completed the acquisition of 100% of the issued shares of Cipla Medpro South Africa Ltd. for an aggregate consideration of ZAR 4507mn (Rs 2707 crore). On 17 April 2013, Cipla announced the launch of the first biosimilar of Etanercept in India for the treatment of rheumatic disorders. On 20 February 2014, Cipla and MSD announced the formation of an India-specific strategic partnership whereby Cipla will have a non-exclusive license to market, promote and distribute MSD's raltegravir 400mg tablet, under a different brand name in India. The drug is used for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. On 12 May 2014, Cipla through its wholly owned subsidiary, Cipla (EU) Limited announced $21 million two-phase investment in Chase Pharmaceuticals Corporation Inc., US (Chase) to support Alzheimer's disease drug development. On 19 June 2014, Cipla announced that it has collaborated with Hetero to launch a biosimilar of the drug Darbepoetin alfa' under the brand name Actorise'. The product is indicated for the treatment of anaemia caused due to chronic kidney disease. On 7 July 2014, Cipla announced its intention to make investments of up to 100 million in its UK subsidiary over the next few years. The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as well as research and development, clinical trials and further expansion internationally and in the UK. In its bid to enter the markets of Czech Republic and Slovaki, Cipla on 8 September 2014 announced commercial collaboration with UK-based S&D Pharma. On 15 September 2014, Cipla announced that it had signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of Sofosbuvir mono, Ledipasvir mono, the fixed-dose combination of Ledipasvir/Sofosbuvir with each other and the combination of Sofosbuvir or Ledipasvir with other active substances, for the treatment of hepatitis C. On 18 September 2014, Cipla announced that it has granted Salix Pharmaceuticals, Inc., a US-based speciality pharmaceutical company, exclusive rights under certain patent applications in the Rifaximin Complexes' patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. On 8 October 2014, Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro announced that it had entered into sales and distribution arrangement with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world for the territory of South Africa. As per the tie-up, Cipla Medpro, a 100% subsidiary of Cipla Limited, will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. On 9 February 2015, Cipla announced that its wholly owned subsidiary, Cipla (EU) Limited, U.K. has entered into a joint venture (JV) agreement with Cipla's existing business partners in Morocco - Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and The Pharmaceutical Institute (PHI). This JV is aimed at strengthening Cipla's presence in Morocco, which is in-line with its global growth strategy to build front-end presence in key markets. On 13 February 2015, Cipla announced that it has been awarded USD 188.95 million of Global Fund ARV Tender for anti-retrovirals drugs. The Global Fund is a 21st- century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. On 21 July 2015, Cipla announced that its board of directors approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II Limited or its affiliates, in its newly launched consumer healthcare business which is under incorporation. On 4 September, 2015, Cipla announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc for $550 million in an all cash transaction. InvaGen Pharmaceuticals is a leading generic pharmaceutical company in the US. Exelan Pharmaceuticals is a privately held sales and marketing company, with a focus on generic pharmaceuticals for the government and institutional market in the US. On 18 February 2016, Cipla announced that its UK arm, Cipla (EU) Limited had successfully completed the acquisition of InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The acquisition was made by Cipla (EU) Limited through a wholly owned special purpose vehicle which would merge into InvaGen Pharmaceuticals Inc. after the acquisition. On 8 October 2015, Cipla announced that its South African subsidiary Cipla Medpro (Pty) Ltd. entered into an exclusive agreement with the world's largest vaccine manufacturer, Serum Institute of India (SII) to provide vaccines in South Africa. On 29 October 2015, Cipla announced that it had entered into a definitive agreement to sell its entire 25% stake in Biomab Holding Limited, Hong Kong (BHL) to Biomab Brilliant Limited, British Virgin Islands which holds the remaining 75% stake in BHL, for a total consideration of USD 25,775,000. Biomab Holding Limited is focused on developing Biosimilars for the Chinese market. On 21 December 2015, Cipla announced the launch of generic drug Ledipasvir-Sofosbuvir in India under the brand name Hepcvir-L. Hepcvir-L is the first once-a-day, fixed-dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. On 6 January 2016, BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India. On 12 October 2016, Cipla announced that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility, indicating formal closure of the US FDA inspection conducted in July/August, 2015. On 23 November 2016, Cipla announced that Chase Pharmaceuticals Corporation, a Delaware based corporation (Chase) in which Cipla Limited's UK arm, Cipla (EU) Limited (Cipla UK) has 16.7% stake, has been acquired by a subsidiary of Allergan, plc. Allergan agreed to pay $125 million upfront plus potential regulatory and commercial milestones of up to $875 million to the shareholders of Chase. Cipla UK acquired a minority stake in Chase in May 2014 via a syndicated venture investment. On 17 February 2017, Cipla announced the launch of adult Hepatitis B vaccine in India. Under a co-exclusive agreement with Serum Institute of India Private Limited (SII), Cipla will market the vaccine for adults while SII will market it for adults and children. On 4 March 2017, Cipla announced that it had entered into agreements, through its Wholly Owned Subsidiary Inyanga Trading 386 Proprietary Limited (Inyanga), with the group companies of Ascendis Health Limited, South Africa for divesting its animal health business in South Africa and Sub-Saharan Africa. On 6 April 2017, Cipla announced that its wholly owned subsidiary in USA Cipla USA Inc. signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity. On 30 November 2017, Cipla announced that it had received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. During FY18, Anmarat (Pty) Limited was acquired in South Africa as a part of strategy to strengthen OTC portfolio and Cipla Technologies LLC was incorporated in USA to build speciality product portfolio for Cipla. During FY18, two non-operating companies viz., Meditab Specialities New Zealand Ltd and Cipla Pharma Nigeria Ltd were deregistered. As a part of strategy, the Company has divested its entire stake in Cipla Croatia d.o.o., Croatia, Al Jabal For Drugs And Medical Appliances Company Ltd, Yemen, Cipla Agrimed Proprietary Ltd and Cipla Vet Proprietary Ltd., in South Africa. As on 31st March, 2018, it has 49 subsidiaries and 1 associate. During the FY18,the company invested Rs 816 crore on capital expenditure, over Rs 300 crore lower than the previous year. During the FY19, Madison Pharmaceuticals Inc. was incorporated in USA and Cipla Gulf FZ- LLC in Dubai for strengthening its business operations. In South Africa, Mirren (Pty) Limited was acquired as a part of strategy to strengthen its OTC portfolio. In USA, 33.3% stake was acquired in Avenue Therapeutics Inc. for building specialty business in USA. The Company's wholly owned subsidiary Goldencross Pharma Private Limited acquired minority stake i.e. 11.71% in Wellthy Therapeutics Private Limited. During the 2018-19, 4 non-operating subsidiaries viz. Xeragen Laboratories (Pty) Limited, Galilee Marketing (Pty) Ltd, Med Man Care (Pty) Ltd in South Africa and Cipla FZE in Dubai were liquidated. The company had 48 subsidiaries and 2 associates as on 31st March, 2019. During the FY2019, the Company invested Rs 504 crore in capital expenditure (net off sales proceeds), which is lower by Rs 200 crore from the previous year. During the FY2020, Incorporation of Cipla Pharmaceuticals Limited in India for setting up facilities for DPI dosage and for further expansion of MDI and FFS Respule Dosage, Cipla (Colombia) SAS in Colombia and Cipla (China) Pharmaceutical Co. Limited in China for strengthening its business portfolio in foreign markets. Also incorporation of Cipla (Jiangsu) Pharmaceutical Co, Limited as Joint venture between Cipla (EU) Limited and Jiangsu Acebright Pharmaceutical Co. Limited for exploring business opportunities and manufacture of pharmaceutical products in China. The company also acquired the remaining 40% stake in Cipla Pharma Lanka Private Limited (CPL) by Cipla (EU) Limited, to further strengthen its presence in Sri Lanka. Upon acquisition CPL has become a wholly owned subsidiary of Cipla (EU) Limited. Also acquired 30% stake in Brandmed (Pty) Limited by Cipla Medpro South Africa (Pty) Limited to enhance its diversified portfolio in the noncommunicable diseases area. The company also acquired 26% stake in AMPSolar Power Systems Private Limited to enhance the proportion of renewable (solar) based power consumption, and to comply with regulatory requirement for captive power consumption under electricity laws. The company also liquidated Tasfiye Halinde Cipla ila Ticaret Anonim Sirketi, Turkey. The company had 51 subsidiaries and 4 associates as on 31st March, 2020. Cipla won the Digital Supply Chain Enterprise Award' at the 9th edition of the Manufacturing Supply Chain Awards 2020. During the FY2021, The Group has divested its stake in two of its subsidiaries namely Quality Chemical Limited (Group share - 51.18%) and Anmarat Proprietary Limited (wholly owned subsidiary). The Board in its meeting held on 29th January, 2021 has approved a draft scheme of arrangement (Scheme) which entails demerger of the US business undertaking (Demerged Undertaking 1) of Cipla Limited (Demerged Company) into its wholly-owned subsidiary, Cipla BioTec Limited (Resulting Company 1) and consumer business undertaking (Demerged Undertaking 2) of Cipla Limited into its wholly-owned subsidiary, Cipla Health Limited (Resulting Company 2) pursuant to Sections 230 to 232 and the other relevant provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said Scheme would be subject to the receipt of requisite approvals including from the National Company Law Tribunal, BSE Limited, National Stock Exchange of India Limited and Securities and Exchange Board of India, the shareholders and/or creditors of the Demerged Company, Resulting Company 1 and Resulting Company 2. On 30th March 2021, the Company made a strategic investment of Rs 40 Crore in ABCD Technologies LLP. On 10th May, 2021, Cipla Technologies LLC (Ciptec'), a subsidiary of the Group has received an anticipatory material breach notice under Development and Commercialization Agreement with Pulmatrix on co-development of Pulmazole. The Company will suitably respond to the said notice. As on 31 March 2021,the company had 55 subsidiaries and 5 associate companies under its roof.

Cipla Ltd Directors Reports

Dear Members,

The Board of Directors is pleased to submit its report on the performance of the Company along with the audited standalone as well as consolidated financial statements for the year ended 31st March, 2021.

Financial Summary and State of Affairs

H in Crore

Year ended 31st March, 2021

Year ended 31st March, 2020

Particulars Standalone Consolidated Standalone Consolidated
Gross total revenue 13,900.58 19,159.59 12,659.15 17,131.99
Profit before tax and exceptional items 3,350.66 3,290.06 2,964.31 2,178.18
Profit for the year (after tax and
attributable to shareholders) 2,468.28 2,404.87 2,318.17 1,546.52
Other comprehensive income for the
year (not to be reclassified to P&L) 13.71 (37.46) (15.30) (9.42)
Other comprehensive income for the
year (to be reclassified to P&L) 27.75 198.95 (49.13) (119.98)
Surplus brought forward from last
balance sheet 12,479.72 11,117.88 10,828.56 10,251.31
Profit available for appropriation 14,961.71 13,536.98 13,131.43 11,782.08
Appropriations:
Dividend - - (564.26) (564.26)
Tax on dividend - - (87.45) (99.94)
Surplus carried forward 14,961.71 13,536.98 12,479.72 11,117.88

The financial results and the results of operations, including major developments have been discussed in detail in the Management Discussion and Analysis Report.

The standalone as well as the consolidated financial statement have been prepared in accordance with the Indian Accounting Standards (Ind AS).

Share Capital

During the year under review, the Company issued and allotted 2,27,950 equity shares to its employees under the Employee Stock Option Scheme 2013-A. As a result, the issued, subscribed and paid-up share capital of the Company increased from H 1,61,24,70,658/- (divided into 80,62,35,329 equity shares of H 2/- each) to H 1,61,29,26,558/- (divided into 80,64,63,279 equity shares of H 2 each). The equity shares issued under the Employee Stock Option Scheme 2013-A rank pari- passu with the existing equity shares of the Company.

Dividend

In line with the Dividend Distribution Policy of the Company, we recommend a final dividend of H 5/- per equity share (i.e. 250% of face value) for the financial year ended 31st March, 2021. The dividend, if approved at the Annual General Meeting (AGM), will be paid to those members whose names appear in the Register of Members as on close of Tuesday, 10th August, 2021. The total dividend payout will be approximately H 403.23 crores, 16.34 % of the standalone profit after tax of the

Company. The Dividend Distribution Policy is uploaded on the website at https://www.cipla.com/sites/default/ files/2019-01/Dividend%20Distribution%20Policy.pdf

Reserve

During the year, as per provisions under IndAS 102 - Share-based Payment, the Company has transferred an amount of H 2.02 crores to the General Reserve from the Share Based Payment Reserve, due to lapse of vested options under the Cipla Employee Stock Scheme 2013 - A.

Nature of business

The Company is engaged in the business of development, manufacturing, sale and distribution of pharmaceutical generic medicines, branded generic medicines, specialty medicines, and OTC consumer wellness products. The Company also offers in-licensed patented medicines and in-licensed diagnostics kits for

COVID-19. During the year, there has been no change in the nature of business of the Company.

Management Discussion and Analysis Report

Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the Management Discussion and Analysis Report for the year under review, has been presented in a separate section on page 129, forming part of this report.

Corporate Social Responsibility (CSR)

A detailed report on Cipla's various CSR initiatives has been provided in the Social Capital section forming part of Integrated Report on page 108 and Annual Report on CSR initiatives, as required under Section 135 of the Companies Act, 2013 (Act) which is annexed as Annexure I to this report on page 160. Details of the CSR Committee composition, role and meetings, etc. have been provided in the Report on Corporate Governance on page 200.

Business Responsibility Report

In compliance with the provisions of Regulation 34 of the Listing Regulations, the Business Responsibility Report (BRR) is presented in a separate section on page 176 of this report. Since the Company has adopted International Integrated Reporting Council (IIRC) framework for publishing the Annual Report, reports on the nine principles of the National Voluntary Guidelines on social, environmental and economic responsibilities of business as framed by the Ministry of Corporate Affairs (MCA), Government of India, is provided in relevant sections of the Integrated Report with suitable references in the BRR.

Corporate Governance

In compliance with Regulation 34 read with Schedule V of the Listing Regulations, a Report on Corporate Governance for the year under review, is presented in a separate section on page 183 of this report.

A certificate from M/s. BNP & Associates, Company Secretaries, Mumbai confirming compliance with the conditions of corporate governance, as stipulated under the Listing Regulations, is annexed as Annexure II to this report.

Directors' Responsibility Statement

Pursuant to Section 134(3)(c) of the Act, it is confirmed that the directors have:

i. Followed applicable accounting standards in the preparation of the annual accounts and there are no material departures for the same;

ii. Selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on 31st March, 2021 and of the profit of the Company for the year ended 31st March, 2021;

iii. Taken proper and sufficient care for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

iv. Prepared the annual accounts on a going concern basis;

v. Laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and

vi. Devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The details of Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo as required under Section 134(3)(m) of the Act, read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed as Annexure III to this report.

Employee Stock Option Scheme

Cipla Employee Stock Option Scheme 2013-A

The Company has an Employee Stock Option (ESOP) Scheme, namely "Employee Stock Option Scheme 2013- A" (ESOP Scheme) that acts as a retention tool and helps to promote a culture of ownership among employees of the Company and its subsidiary companies. There was no change in the ESOP scheme during the financial year under review and no employee was granted options equal to or exceeding 1% of the issued share capital of the Company.

Cipla Employee Stock Appreciation Rights Plan 2021

In order to align employee rewards with the Company's long-term growth and shareholder value creation and also to attract, retain and motivate the best available talent, pursuant to the shareholder's approval dated 25th March, 2021 the "Cipla Employee Stock Appreciation Rights Scheme 2021" (ESAR Scheme) for issue of stock appreciation rights was implemented by the Board during FY 2020-21. Under the Scheme, the ESAR grantees are entitled to receive appreciation in the value of vested ESARs in the form of equity shares. During the year, no ESARs were granted under the scheme.

The NRC administers the ESOP Scheme and the ESAR Scheme (collectively referred to as 'Schemes'). The Schemes are in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 (SBEB Regulations). Details of the Schemes have also been provided in Note No. 42 of the standalone financial statement. The disclosure in compliance with SBEB Regulations, is available on the Company's website at https://www.cipla.com/ investors/annual-reports.

In compliance with the requirements of the SBEB Regulations, a certificate from auditors, confirming implementation of the ESOP Scheme and the ESAR Scheme in accordance with the said regulations and shareholder's resolution, will be available for electronic inspection by the members during the AGM of the Company.

Human Resources

Information required under Section 197(12) of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in Annexure IV to this report.

Information required under Section 197(12) of the Act read with rule 5(2) and rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in a separate exhibit forming part of this report and is available on the website of the Company at https://www.cipla.com/ investors/annual-reports.

Particulars of Loans, Guarantees and Investments

Particulars of loans, guarantees and investments under Section 186 of the Act have been provided in Note No. 44 to the standalone financial statements.

Annual Return

The Annual Return as on 31st March, 2021 has been placed on the website of the Company and can be accessed at https://www.cipla.com/investors/annual-reports.

Vigil Mechanism

The Company is committed to foster an environment of honest and open communication and discussion, consistent with our values. The Company has formulated a Whistle-Blower Policy, which lays down the process to convey genuine concerns to the Management and seek resolution towards the same without fear of retaliation. This policy covers reporting of any violation, wrongdoing or non-compliance, including without limitation, those relating to the Code of Conduct, policies and standard procedures of the Company, and any incident involving leak or suspected leak of unpublished price sensitive information (UPSI) or unethical use of UPSI in accordance with (or under) the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Directors, employees and external stakeholders can report their genuine concerns either in writing or by email to the Chairperson of the Ethics Committee or to the Chief Internal Auditor at ethics@cipla. com or to the Chairperson of the Audit Committee at audit.chairman@cipla.com. An Ethics Committee comprising of the Global Chief People Officer (GCPO) as Chairperson, the Global Chief Financial Officer (GCFO), the Global General Counsel (GC) and the Global Chief Internal Auditor as members, investigates whistle-blower complaints. A report on the functioning of the mechanism, including the complaints received and actions taken, is presented to the Audit Committee on a quarterly basis. The Whistle-Blower Policy is available on the Company's website at https://www. cipla.com/sites/default/files/2020-02/Whistle%20 Blower%20Policy%20V3-%20Final.pdf.

Detailed update on the functioning of the Whistle-Blower Policy and compliance with the Code of Conduct has also been provided in the Report on Corporate Governance, on page 204.

Prevention of Sexual Harassment of Women at Workplace

The Company is committed to providing a safe and conducive work environment to all its employees and associates. The Company has a Policy on Prevention of Sexual Harassment at Workplace, which is available on the Company website at https://www.cipla.com/ sites/default/files/1558508425_POSH-%20Cipla.pdf. All employees, consultants, trainees, volunteers, third parties and/or visitors at all business units or functions of the Company, its subsidiaries and/or its affiliated or group companies are covered by the said policy. Adequate workshops and awareness programmes against sexual harassment are conducted across the organisation.

The Company has constituted an Internal Complaints Committee in compliance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and is fully compliant. The Audit Committee oversees compliance at regular intervals.

Details of complaints received/disposed during FY 2020-21 are provided in the Report on Corporate Governance on page 207.

Related Party Transactions

A detailed note on procedure adopted by the Company in dealing with contracts and arrangements with related parties has been provided in the Report on Corporate Governance on page 206.

All contracts, arrangements and transactions entered by the Company with related parties during FY 2020-21 were in the ordinary course of business and on an arm's length basis. During the year, the Company did not enter into any transaction, contract or arrangement with related parties, that could be considered material in accordance with the Company's Policy on Dealing with Related Party Transactions. Accordingly, the disclosure of related party transactions in Form AOC-2 is not applicable. However, disclosure on related party transactions as per IND AS-24 has been provided under Note No. 41 of the standalone financial statements on page 290 and Note No. 48 of the consolidated financial statements on page 409.

During the year, the Company amended the Policy on Dealing with Related Party Transactions ('RPT Policy') to simplify the process of transaction approval sought from the Audit Committee. The RPT Policy is available on the Company's website at https://www.cipla.com/sites/ default/files/2020-06/Policy%20on%20dealing%20 with%20Related%20Party%20Transactions.pdf

Internal Financial Control and its adequacy6

Cipla has laid down an adequate system of internal controls, policies and procedures for ensuring orderly and efficient conduct of the business, including adherence to the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting records and timely preparation of reliable financial disclosures.

The current system of IFC is aligned with the statutory requirements and is in line with the globally accepted risk- based framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. The IFC are adequate and operating effectively.

Effectiveness of IFC is ensured through Management reviews, controlled self-assessment and independent testing by the Internal Auditor.

Risk Management

The Board of Directors has formed an Investment and Risk Management Committee (IRMC) which oversees the Enterprise Risk Management (ERM) process. An update on ERM activities is presented and deliberated upon in the IRMC meetings on quarterly basis and periodically at the Board level from time to time but at least once a year. The Audit Committee has additional oversight in the area of financial risks and controls. The major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. In terms of the provisions of Section 134 of the Act, a detailed note on Risk Management has been provided on page 52 of this report.

Board Evaluation

In order to ensure that the Board and board committees are functioning effectively and to comply with statutory requirements, the annual performance evaluation of the Board, board committees and individual directors was conducted during the year. The evaluation was carried out based on the criteria and framework approved by the NRC. A detailed disclosure on the parameters and the process of Board evaluation as well as the outcome has been provided in the Report on Corporate Governance on page 189.

Subsidiaries, Associates and Joint Ventures

At the beginning of the year, the Company had 51 subsidiaries and 4 associates, as against 46 subsidiaries and 5 associates as on 31st March, 2021. During the year, the following companies were incorporated, acquired, liquidated or divested:

o Incorporation of Cipla Therapeutics Inc., USA, to expand business in specialty segment in the US market.

o Acquisition of 21.85% stake in GoApptiv Private Limited to enable wider reach of key brands in the tier 3+ towns through GoApptiv's solutions for end-to-end brand marketing and channel engagement.

o Amalgamation of Cipla Pharma Lanka (Private) Limited with Breath Free Lanka (Private) Limited to eliminate duplication resulting in operational synergies and reduction of costs together with focused operational efforts, rationalisation, standardisation and simplification of business processes.

o Divestment of stake in the following subsidiaries:

o Anmarate (Pty) Limited, South Africa by Cipla Medpro South Africa (Pty) Limited, South Africa (wholly owned subsidiary) as a part of over-all group simplification process.

o Quality Chemicals Limited, Uganda, for eliminating complexity and enhancing focus by exiting non-core business.

o Voluntary liquidation of following wholly-owned subsidiaries as a part of internal reorganisation:

o Cipla (Mauritius) Limited, Mauritius

o Cape to Cairo Exports (Pty) Limited, South Africa

o Cipla (UK) Limited, UK

Details of these subsidiaries and associates are set out on page 355 of the Annual Report. Pursuant to Section 129(3) of the Act read with Rule 5 of the Companies (Accounts) Rules, 2014, a statement containing salient features of the financial statement of the subsidiary and associate companies in form no. AOC-1 is given on page 417 of the Annual Report. The statement also provides details of the performance and the financial position of each of the subsidiaries and associates. The consolidated financial statements presented in this Annual Report include financial results of the subsidiary and associate companies.

Copies of the financial statements of the subsidiary companies are available on the Company's website https://www.cipla.com/investors/annual-reports.

Scheme of Arrangement

During the year, the Board of Directors had approved the Scheme of Arrangement ("Scheme") between the Company ("Demerged Company"), Cipla BioTec Limited ("Resulting Company 1") and Cipla Health Limited ("Resulting Company

2") and their respective shareholders for the transfer of India based US business undertaking ("Demerged Undertaking 1") of the Demerged Company into the Resulting Company 1 and transfer of consumer business undertaking ("Demerged Undertaking 2") of the Demerged Company to Resulting Company 2 by way of demerger. The Company has received all necessary approvals and is in the process of filing an application before the National Company Law Tribunal for approval of the Scheme.

The Scheme details, rationale and benefits, along with other documents, are available on the Company's website at https://www.cipla.com/investors/scheme- arrangement

Directors and Key Managerial Personnel

At the 84th AGM of the Company held on 27th August, 2020, the shareholders approved the (i) re-appointment of Ms Naina Lal Kidwai as Independent Director for a second term of five years effective 6th November, 2020, (ii) re-appointment of Ms Samina Hamied as Executive Vice-Chairperson for a period of five years effective 10th July, 2020, and (iii) re-appointment of Mr S Radhakrishnan as non-executive director liable to retire by rotation.

On the recommendation of the NRC, the Board recommends the following appointments /

re-appointment: (i) re-appointment of Mr M K

Hamied, who retires by rotation and being eligible has offered himself for re-appointment as director liable to retire by rotation (ii) re-appointment of Mr Umang Vohra as Managing Director and Global Chief Executive Officer for a period of five (5) years commencing from 1st April, 2021 till 31st March, 2026

(iii) appointment of Mr Robert Stewart as Independent Director of the Company for a for a period of five (5) years commencing from 14th May, 2021 to 13th May, 2026.

In the opinion of the Board, all the directors, as well as the directors proposed to be appointed / re-appointed, possess the requisite qualifications, experience and expertise and hold high standards of integrity. All of the independent directors except Mr. Robert Stewart, are exempt from the requirement of passing the proficiency test. Unless exempted, Mr. Robert Stewart will be required to pass the proficiency test within the permissible time limit. The list of key skills, expertise and core competencies of the Board of Directors is provided in the Report on Corporate Governance at page 186 of this Annual Report.

Details such as brief resumes, nature of expertise in specific functional areas, names of companies in which the above-named directors hold directorships, committee memberships/ chairpersonships, shareholding in Cipla, etc. are furnished in the Notice of the AGM.

The criteria for determining qualification, positive attributes and independence of a director are given in the Nomination, Remuneration and Board Diversity Policy, disclosed as Annexure E to the Report on Corporate Governance. During the year, the Board, on the recommendation of the NRC, amended the policy twice to add the evaluation criteria while appointing any Key Managerial Personnel or Senior Management Personnel, and to modify the sitting fees for nonexecutive directors.

As on 31st March, 2021, the Company has the following Key Managerial Persons (KMP) as per Section 2(51) of the Act:

Sr. No Key Managerial Personnel Designation
1 Ms Samina Hamied Executive ViceChairperson
Managing Director and
2 Mr Umang Vohra Global Chief Executive Officer
3 Mr Kedar Upadhye Global Chief Financial Officer
4 Mr Rajendra Chopra Company Secretary and Compliance Officer

Except Dr Peter Mugyenyi and Mr S Radhakrishnan, none of the other directors, including the Managing Director and Global CEO and the Whole-Time Director, received any remuneration or commission from any of the Company's subsidiaries.

Declaration by Independent Directors

All independent directors have submitted requisite declaration confirming that they (i) continue to meet the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations; and (ii) are compliant of the Code of Conduct laid down under Schedule IV of the Act.

All the directors have confirmed that they are not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Board Committees and Number of Meetings of the Board and Board Committees

The Board has following committees:

i) Audit Committee

ii) Nomination and Remuneration Committee

iii) Corporate Social Responsibility Committee

iv) Stakeholders Relationship Committee

v) Investment and Risk Management Committee

vi) Operations and Administrative Committee

The Board constituted one special committee i.e. Committee of Independent Directors pursuant to the requirement of the SEBI Circular No. SEBI/HO/CFD/ DIL1/CIR/P/2020/249 dated 22nd December 2020. All the independent directors were appointed as the members of the Committee.

All the recommendations of the board committees, including the Audit Committee, were accepted by the Board.

The Board met eight times during the year under review. The maximum gap between two consecutive board meetings did not exceed 120 days. A detailed disclosure on the Board, its committees, its composition, the detailed charter and brief terms of reference, number of board and committee meetings held, and attendance of the directors at each meeting is provided in the Report on Corporate Governance, which forms part of this report.

Auditor and Auditor's Report

M/s. Walker Chandiok & Co LLP, Chartered Accountants were appointed as Statutory Auditors of the Company at the Annual General Meeting (AGM) held on 28th September, 2016, for a term of five consecutive years i.e. upto the conclusion of ensuing 85th AGM.

As per the provisions of Section 139 of the Act, the Board of Directors of the Company, on the recommendation of the Audit Committee, recommends re-appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants for a further period of five years i.e. upto the conclusion of 90th AGM.

M/s. Walker Chandiok & Co LLP, Chartered Accountants,

(i) have expressed their willingness to be reappointed for a further term, (ii) have submitted their confirmation to the effect that they continue to satisfy the criteria provided in Section 141 of the Act and (iii) that their appointment is within the limits prescribed under Section 141 (3)(g) of the Act.

A resolution proposing re-appointment of M/s. Walker Chandiok & Co LLP as the Statutory Auditor of the Company and their remuneration pursuant to Section 139 of the Act, along with the explanatory statement, forms part of the Notice of 85th AGM.

The Auditor's Report for FY 2020-21 does not contain any qualification, reservation, adverse remark or disclaimer. Further, there are no instances of any fraud reported by the Auditors to the Audit Committee or to the Board pursuant to Section 143(12) of the Act.

Secretarial Auditor and Secretarial Audit Report

The Secretarial Audit Report for the financial year ended 31st March, 2021 is annexed as Annexure V to this report.

The Board of Directors, on the recommendation of the Audit Committee, has re-appointed M/s BNP & Associates, Company Secretaries, Mumbai to conduct the secretarial audit of the Company for FY 2021-22. They have confirmed their eligibility for the re-appointment.

The Secretarial Audit Report does not contain any qualification, reservation, disclaimer or adverse remark.

Cost Auditor and Cost Audit Report

The Board of Directors, on the recommendation of the Audit Committee, had appointed Mr D H Zaveri, practising Cost Accountant (Fellow Membership No. 8971) as Cost Auditor to conduct the audit of Company's cost records for the financial year ended 31st March, 2021. The Cost Auditor has confirmed that they are not disqualified pursuant to the provisions of Section 141 of the Act read with Section 139 and 148 of the Act. The Cost Auditor will submit their report for the FY 2020-21 on or before the due date. The Cost Audit Report, for the year ended 31st March, 2020, was filed with the Central Government within the prescribed time. The Company maintains the Cost Records as per the provisions of Section 148(1) of the Act.

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, since the remuneration to be paid to the Cost Auditor for FY 2021-22 is required to be ratified by the members, the Board of Directors recommends the same for approval by members at the ensuing AGM. The proposal forms part of the Notice of the AGM.

Key Initiatives with respect to Stakeholder Relationship, Customer Relationship, Environment, Sustainability, Health and Safety

The key initiatives taken by the Company with respect to stakeholder relationship, customer relationship, environment, sustainability, health and safety are provided separately in various Capitals in the Integrated Report section of the report.

Other Disclosures

During the financial year under review:

o the Company has complied with the applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively.

o the Company issued and allotted equity shares under the ESOP scheme and there were no instances wherein the Company failed to implement any corporate action within the statutory time limit.

o the Company did not accept any deposit within the meaning of Sections 73 and 74 of the Act read with the Companies (Acceptance of Deposits) Rules, 2014 and accordingly no amount on account of principal or interest on public deposits was outstanding as on 31st March, 2021.

o the Company has not issued shares with differential voting rights and sweat equity shares during the year under review.

o no significant or material orders were passed by the regulators or courts or tribunals which could impact the going concern status of the Company and its future operations.

o no material changes and commitments have occurred after the close of the year till the date of this report which may affect the financial position of the Company.

Acknowledgements

We wish to place on record our appreciation of the Governments of the countries where the Company has its operations. We also thank the Ministry of Chemicals & Fertilizers, India; the Central Government; State Governments and other regulatory bodies / authorities; banks; business partners; shareholders; medical practitioners and other stakeholders; for the assistance, co-operation and encouragement extended to the Company. We would also like to place on record our deep sense of appreciation to the employees for their contribution and services.

On behalf of the Board
Date: 14th May, 2021 Y K Hamied
Place: Mumbai Chairman

   

Cipla Ltd Company Background

Y K HamiedUmang Vohra
Incorporation Year1935
Registered OfficeCipla House Peninsula Buss Par,Ganpatrao Kadam Mg Lower Parel
Mumbai,Maharashtra-400013
Telephone91-22-24826000,Managing Director
Fax91-22-24826120
Company SecretaryRajendra Chopra
AuditorWalker Chandiok & Co LLP
Face Value2
Market Lot1
ListingBSE,Luxembourg,MSEI ,NSE,
RegistrarKFin Techologies Pvt Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda ,Hyderabad-500032

Cipla Ltd Company Management

Director NameDirector DesignationYear
Y K Hamied Chairman (Non-Executive) 2021
M K Hamied Vice Chairman 2021
S Radhakrishnan Non-Exec & Non-Independent Dir 2021
Ashok Sinha Non-Exec. & Independent Dir. 2021
Peter Mugyenyi Non-Exec. & Independent Dir. 2021
Adil Zainulbhai Non-Exec. & Independent Dir. 2021
Punita Lal Non-Exec. & Independent Dir. 2021
Samina Hamied Executive Vice Chairperson 2021
Naina Lal Kidwai Non-Exec. & Independent Dir. 2021
Umang Vohra Managing Director & Global CEO 2021
Rajendra Chopra Company Secretary 2021
Robert A Stewart Independent Director 2021
P R Ramesh Addtnl Independent Director 2021

Cipla Ltd Listing Information

Listing Information
NIFTY
BSE_500
BSE_HC
BSE_100
BSE_200
BSEDOLLEX
CNX500
CNXPHARMA
CNX100
CNX200
BSEGREENEX
NFTALPHA50
BSECARBONE
NI15
NFT100EQWT
BSEALLCAP
BSELARGECA
BSEMANUFAC
SENSEX50
ESG100
LMI250
BSEDSI
NFT50EQWT
NFT100LV30
BSE100LTMC

Cipla Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sales NA 00012220.22
Export Incentives NA 000249.96
Royalty NA 00056.02
Other Operating Revenue NA 00034.15
Scrap Sales NA 00029.55
Marketing & Other Product Lic.NA 00027.29
GST area Based Incentive NA 00022.5
Technical Know-how fees NA 00016.72
Rendering of Services NA 0002.74
Service Income NA 0000
Others-Traded NA 0000
Excise Duty NA 0000
Others No 0000
Bulk Drugs (Including Malts) MT 0000
Bulk Drugs-Traded NA 0000
Aerosols No 0000
Aerosols-Traded NA 0000
Creams MT 0000
Creams-Traded NA 0000
Injections/Sterile Solutions KL 0000
Injections-Traded NA 0000
Liquids KL 0000
Liquids-Traded NA 0000
Tablets & Capsules No 0000
Tablets & Capsules NoM0000
Tablets & Capsules-Traded NA 0000
Agro Chemical Formulations MT 0000

Contact us Contact us